Senate panel approves insulin cost cap, as affordability at-large looms large over midterms

A Senate panel advanced bipartisan legislation that would cap insulin costs for Americans with private insurance, folding drug pricing, generics policy and health care affordability into a broader midterm policy debate.

What you’ll learn

• How the INSULIN Act would cap private insurance cost-sharing for insulin
• What generics, biosimilar and uninsured-patient provisions are included in the bill
• Why the measure reflects broader affordability politics ahead of the midterms

Why this matters

Health care affordability is becoming a defining policy and political issue before Election Day, with lawmakers testing which cost-focused proposals can gain traction. POLITICO Pro helps health care organizations track how legislative movement, stakeholder pressure and electoral timing could shape strategy, planning and advocacy.

Fill out the form to read the full POLITICO Pro Bill Analysis.